Circulating tumor DNA marked progressive liver cancer
A personalized PCR test for circulating tumor DNA identified cases of progressive hepatocellular carcinoma,... More
Assessing progression, impact of radiofrequency ablation in Barrett’s esophagus
Patients with Barrett’s esophagus have about a 0.2% annual chance of developing esophageal adenocarcinoma in the 5... More
Low-risk prostate cancer: Replace immediate intervention with immediate contemplation
Men with favorable-risk prostate cancer have a very low risk of disease progression to a lethal phenotype, and they... More
Adjuvant erlotinib showed no benefit in NSCLC patients
Among patients with completely resected non–small-cell lung cancer (NSCLC) whose tumors expressed epidermal growth... More
Shown is a histopathologic image of multiple myoloma with bone marrow aspirates, done with hematoxylin & esoin stains.
Daratumumab monotherapy yielded impressive results in patients with heavily pretreated and refractory multiple myeloma,... More
CMS: We’re ready to accept and process ICD-10 claims
The Centers for Medicare and Medicaid Services says it completed its final Medicare fee-for-service end-to-end testing... More
Dr. Brad Zebrack
WASHINGTON – Chalk up one for the little guy: Community cancer programs are better equipped for delivering psychosocial... More
ACOs generate savings, but few get bonuses
Accountable care organizations (ACOs) accounted for savings of more than $411 million in 2014, according to the Centers... More
Recurrence score assay driving chemo decisions in unexpected ways
Adoption of the 21-gene recurrence score (RS) assay does not appear to have decreased chemotherapy use overall among... More
Dr. Mikkael Sekeres
Cancer patients who arrive in the emergency department with febrile neutropenia (FN) received antibiotics much more... More
Fewer moles linked with more aggressive melanoma
NEW YORK – Consistent with another recently published report but counterintuitive, patients with a high number of nevi... More
Persistent mutations linked to poorer outcomes in AML
Persistent leukemia-associated mutations that can be detected in at least 5% of bone marrow cells at 30 days after... More
Mixed results for cancer survivorship care plan
A cancer survivorship care plan increased the information patients received yet failed to increase patient satisfaction... More
Bone marrow smear from a patient with acute myelomonocytic leukemia.
Clinical outcomes were significantly worse among younger patients with secondary and therapy-related acute myeloid... More
Lenalidomide + rituximab combo effective in recurrent follicular lymphoma
The combination of lenalidomide and rituximab was more active in patients with recurrent follicular lymphoma, compared... More
Secondary CNS lymphoma regimen linked to 41% survival at 5 years
Treatment with high doses of antimetabolites followed by rituximab plus high-dose sequential chemoimmunotherapy and... More
When it comes to giving patients timely care, hematology/oncology practices have an edge over other specialties, the Agency for Healthcare Research and Quality reported. In a composite of five survey questions asking if physicians provided timely ap... More »
A personalized PCR test for circulating tumor DNA identified cases of progressive hepatocellular carcinoma, investigators reported in the September issue of Cellular and Molecular Gastroenterology and Hepatology. Patients with liver cancer who under... More »
Patients with Barrett’s esophagus have about a 0.2% annual chance of developing esophageal adenocarcinoma in the 5 years after initial diagnosis, but the likelihood then rises so that about 9% of all patients will develop cancer by 20 years out, ac... More »
After curative-intent surgery, patients with stage III colon cancer who received oxaliplatin plus capecitabine (XELOX) had improved disease-free survival and overall survival, compared with those who received fluorouracil/folinic acid (FU/FA), accord... More »
Vulvar cancer is a rare gynecologic cancer comprising only 5% of gynecologic malignancies. Given the low incidence of disease, many primary providers and even obstetricians and gynecologists many never encounter a case. Increased awareness of vulvar ... More »
With the race to develop cancer immunotherapies escalating and new agents appearing in the clinic, oncologists’ decision-making toolbox will need to evolve. “As immunotherapeutics become increasingly available to patients, clinicians face a majo... More »
S.Y. TAN, M.D.
Question: Which of the following statements regarding statutory caps on malpractice damages is best? A. All states have such a statutory provision. B. The provision limits the recovery of both economic and noneconomic losses. C. It’s constitutio... More »
Transparency, until recently, was rarely associated with health care. Not anymore. For better and sometimes worse, there is a revolutionary movement toward transparency in all facets of health care: transparency of costs, outcomes, quality, service, ... More »
Shaun Hanson et al
Background Treatment outcomes for non-small-cell lung cancer (NSCLC) patients diagnosed at stage IIIA have been analyzed in many studies, which generally involve patients younger and healthier than the average patient with this disease. Objective To... More »
Bart Frizzell et al
Background and objective Our group created and routinely reviewed a dedicated prostate intensity-modulated radiation therapy (IMRT) delivery program. Previously, a retrospective review of our experience demonstrated that a larger bladder volume reduc... More »